2-step hyperinsulinaemic euglycaemic clamp
At the commencement of the two-step hyperinsulinaemic euglycaemic clamp, basal unenriched blood samples were taken. A bolus of [U-Participants were then randomised to receive either AZD4017 400 mg BD (AstraZeneca, UK) and prednisolone 20 mg daily or matched placebo and prednisolone 20 mg daily, for 7 days. They returned on the 6th day of administration for repeat fasting blood tests, 24 h blood pressure and urine collection and also on the 7th day of administration for a repeat 2-step hyperinsulinemic euglycemic clamp and microdialysis. On each day of investigation, trial medications were taken before the procedures were performed (Supplementary Fig. 